Most Read Articles
5 days ago
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
25 Jul 2019
Adding a third drug to achieve the target blood pressure (BP) seems to be more effective than increasing the dose of existing dual therapy without any increase in adverse events, suggest the results of a meta-analysis, adding that early use of triple therapy can help improve hypertension control.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.

Statins safe, effective in children with familial hypercholesterolaemia

10 Jul 2019
Statin, a blood cholesterol-lowering medicine, reduces sharply in blood cholesterol levels among ACS patients.

Statin therapy is safe and effective in the immediate term in children with familial hypercholesterolaemia, a recent study has found.

Researchers evaluated a prospective cohort of 131 children or adolescents (median age, 10.0 years; 51.1 percent male) who were given statins for familial hypercholesterolaemia. Efficacy was assessed according to the proportion of participants who achieved low-density lipoprotein cholesterol (LDL-C) levels <160 mg/dL. Tolerance was measured according to the occurrence of clinical or laboratory side effects.

Over a median treatment duration of 48 months, median LDL-C levels dropped from 209 mg/dL at baseline to 142 mg/dL. The corresponding percentage difference of –32.0 percent was statistically significant (p<0.0001). More than half (67.4 percent) of the participants achieved the therapeutic LDL-C goal.

Similar effects were observed for other lipid biomarkers. Total cholesterol, for instance, dropped by 24.4 percent (p<0.0001) over the study period, going from 283 mg/dL at baseline to 214 mg/dL at the final follow-up. The same was true for high-density lipoprotein cholesterol (58 to 54.5 mg/dL; percentage difference, –6.0 percent; p=0.0025).

Statin therapy was also acceptably safe, being well tolerated by 81.6 percent (n=107) of the participants. Side effects were reported in 19 patients, and none resulted in permanent discontinuation. However, seven patients had to be switched to another class of statin, none of which resulted in the recurrence of side effects.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
25 Jul 2019
Adding a third drug to achieve the target blood pressure (BP) seems to be more effective than increasing the dose of existing dual therapy without any increase in adverse events, suggest the results of a meta-analysis, adding that early use of triple therapy can help improve hypertension control.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.